Importantly, TBX2-AS1, NTF4, PTPRD-AS, ITGA11, RASGRF2-AS1, and HID1-AS1 were identified as potential therapeutic biomarkers for NSCLC. This evidence concerns the gene RASGRF2 and non-small cell lung carcinoma.